Mirum Pharmaceuticals, Inc. (MIRM) Form 10-Q — Nov 3, 2026
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, up roughly 40% year over year, led by Livmarli at $133.4 million. The company now has four approved medicines after the FDA approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in September 2026. The nine-month net loss widened to $898.1 million from $17.6 million a year ago, driven almost entirely by a one-time $726.3 million acquired IPR&D charge from the ~$771.1 million Bluejay Therapeutics acquisition, which brought the brelovitug hepatitis D franchise with positive Phase 3 AZURE-1 data and a potential BLA filing in the first half of 2027.
Key figures
- Revenue
- 185721000
- Total Debt
- $749.0 million aggregate principal of convertible notes
- Revenue Yoy
- +39.6% Q3 YoY; 9M product sales $521.8M vs $372.4M
- Total Assets
- 1026613000
- Cash Position
- $500.5 million unrestricted cash, cash equivalents and investments
- Shares Outstanding
- 65282044
- Q3 livmarli sales
- 133447000
- 2032 notes principal
- 690000000
- Bluejay total consideration
- 771076000
- Q3 bile acid medicine sales
- 52274000
- 2029 notes principal remaining
- 59035000
- Bluejay acquisition iprd charge
- 726300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.